Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Aronora (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Aronora (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
multiplier
item
Sep. 30, 2019
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs       $ 53,000 $ 14,650
Contingent consideration under RPAs, AAAs, and CPPAs       3,000 7,000
Acquisition of royalty and commercial payment receivables       45,000  
Credit losses on purchased receivables       $ 30,904 1,575
Aronora | Royalty Purchase Agreement          
Agreements          
Number of drug candidates | item 5        
Non-royalties to be received (as a percent) 10.00%        
Future non-royalty payments to be received (as a percent) 5.00%        
Multiplier for cumulative amount of consideration paid | multiplier 2        
Payments of consideration under RPAs, AAAs and CPPAs $ 6,000 $ 3,000      
Contingent consideration under RPAs, AAAs, and CPPAs 3,000        
Threshold amount of cumulative royalties on net sales per product 250,000        
Maximum royalty milestone payments to be paid per product 85,000        
Acquisition of royalty and commercial payment receivables 9,000        
Credit losses on purchased receivables     $ 9,000    
Write off of allowance for credit losses     $ 9,000    
Allowance for credit losses         $ 0
Aronora | Royalty Purchase Agreement | Minimum          
Agreements          
Threshold amount of cumulative royalties on net sales per product 25,000        
Aronora | Royalty Purchase Agreement | SVB Loan          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs $ 3,000        
Aronora | Royalty Purchase Agreement | Bayer Products          
Agreements          
Number of drug candidates | item 3        
Number of drug candidates subject to exclusive license option | item 1        
Royalties entity has right to receive (as a percent) 100.00%        
Non-royalties to be received (as a percent) 10.00%        
Contingent future cash payment for each product $ 1,000        
Aronora | Royalty Purchase Agreement | Bayer Products | Maximum          
Agreements          
Contingent consideration under RPAs, AAAs, and CPPAs $ 3,000        
Aronora | Royalty Purchase Agreement | Non-Bayer Products          
Agreements          
Number of drug candidates | item 2        
Non-royalties to be received (as a percent) 10.00%